Objective: To evaluate the anti-gingivitis and anti-plaque efficacy of a dentifrice containing a bioactive glass particulate (NovaMin) and a negative control dentifrice without NovaMin in a 6 week clinical trial. Material and Methods: The study design was a randomized, double-blinded, controlled clinical trial. The protocol was reviewed and approved by the Ethical Committee of the University. One hundred (100) volunteers took part in the study according to the inclusion and exclusion criteria. The subjects received a supragingival prophylaxis to remove all plaque, calculus and extrinsic stain. Following the baseline examination subjects were instructed to brush with their assigned dentifrice and toothbrush. The levels of Silness & Loe Plaque Index (PLI) and Gingival Bleeding Index (PBI) were determined at baseline (BL) and 6 weeks. A Student t-test was used to compare the effect between the test and control group, p value was set at 5% level. Results: Ninety-five subjects (age range 20-48) finished the study. The PBI (BL, 1.14, 6wk 0.47) and PLI (BL 1.54, 6wk 1.29) were significantly reduced over the 6 week period in the test group (n=47) by 58.8% and 16.4% respectively while there was no difference of the PBI (BL 1.18, 6wk 1.02) and PLI (BL 1.60,6wk 1.57) for the control group (n=48). Conclusion: This study demonstrated that a dentifrice containing NovaMin significantly improved oral health as measured by a reduction in gingival bleeding and a reduction in supra-gingival plaque compared with a NovaMin free dentifrice over the 6 week study period. Supported by Wuhan LiBaiSheng Technology Co. Ltd., Wuhan, P.R.China and NovaMin Technology, Inc., Alachua, Florida, USA.

Back to the Dental Materials: IV - Clinical Trials Program
Back to the IADR/AADR/CADR 82nd General Session (March 10-13, 2004)

Top Level Search